217 related articles for article (PubMed ID: 25197661)
21. Detection of MYD88 L265P mutation by real-time allele-specific oligonucleotide polymerase chain reaction.
Jiménez C; Chillón Mdel C; Balanzategui A; Puig N; Sebastián E; Alcoceba M; Sarasquete ME; Conde IP; Corral R; Marín LA; Paiva B; Ruano M; Antón A; Maldonado R; San Miguel JF; González M; García-Sanz R
Appl Immunohistochem Mol Morphol; 2014; 22(10):768-73. PubMed ID: 24992174
[TBL] [Abstract][Full Text] [Related]
22. MYD88 mutation status does not impact overall survival in Waldenström macroglobulinemia.
Abeykoon JP; Paludo J; King RL; Ansell SM; Gertz MA; LaPlant BR; Halvorson AE; Gonsalves WI; Dingli D; Fang H; Rajkumar SV; Lacy MQ; He R; Kourelis T; Reeder CB; Novak AJ; McPhail ED; Viswanatha DS; Witzig TE; Go RS; Habermann TM; Buadi FK; Dispenzieri A; Leung N; Lin Y; Thompson CA; Hayman SR; Kyle RA; Kumar SK; Kapoor P
Am J Hematol; 2018 Feb; 93(2):187-194. PubMed ID: 29080258
[TBL] [Abstract][Full Text] [Related]
23. Clone-specific MYD88 L265P and CXCR4 mutation status can provide clinical utility in suspected Waldenström macroglobulinemia/lymphoplasmacytic lymphoma.
Burnworth B; Wang Z; Singleton TP; Bennington A; Fritschle W; Bennington R; Brodersen LE; Wells DA; Loken MR; Zehentner BK
Leuk Res; 2016 Dec; 51():41-48. PubMed ID: 27890075
[TBL] [Abstract][Full Text] [Related]
24. Detection of MYD88 L265P mutation by next-generation deep sequencing in peripheral blood mononuclear cells of Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.
Nakamura A; Ohwada C; Takeuchi M; Takeda Y; Tsukamoto S; Mimura N; Nagisa OH; Sugita Y; Tanaka H; Wakita H; Aotsuka N; Matsue K; Yokote K; Ohara O; Nakaseko C; Sakaida E
PLoS One; 2019; 14(9):e0221941. PubMed ID: 31483817
[TBL] [Abstract][Full Text] [Related]
25. [Successful detection of MYD88 L265P mutation in Waldenström's macroglobulinemia complicated with myelofibrosis using highly sensitive digital PCR].
Nawata R; Sugiyama A; Harada K; Shinohara K; Yujiri T
Rinsho Ketsueki; 2019; 60(8):903-909. PubMed ID: 31484887
[TBL] [Abstract][Full Text] [Related]
26. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia.
Treon SP; Cao Y; Xu L; Yang G; Liu X; Hunter ZR
Blood; 2014 May; 123(18):2791-6. PubMed ID: 24553177
[TBL] [Abstract][Full Text] [Related]
27. MYD88 mutant lymphoplasmacytic lymphoma/Waldenström macroglobulinemia has distinct clinical and pathological features as compared to its mutation negative counterpart.
Patkar N; Subramanian PG; Deshpande P; Ghodke K; Tembhare P; Mascarenhas R; Muranjan A; Chaudhary S; Bagal B; Gujral S; Sengar M; Menon H
Leuk Lymphoma; 2015 Feb; 56(2):420-5. PubMed ID: 24828863
[TBL] [Abstract][Full Text] [Related]
28. Frequency of MYD88 L256P mutation and its correlation with clinico-hematological profile in mature B-cell neoplasm.
Shekhar R; Naseem S; Binota J; Varma N; Malhotra P
Hematol Oncol Stem Cell Ther; 2021 Sep; 14(3):231-239. PubMed ID: 33217360
[TBL] [Abstract][Full Text] [Related]
29. A mutation in MYD88 (L265P) supports the survival of lymphoplasmacytic cells by activation of Bruton tyrosine kinase in Waldenström macroglobulinemia.
Yang G; Zhou Y; Liu X; Xu L; Cao Y; Manning RJ; Patterson CJ; Buhrlage SJ; Gray N; Tai YT; Anderson KC; Hunter ZR; Treon SP
Blood; 2013 Aug; 122(7):1222-32. PubMed ID: 23836557
[TBL] [Abstract][Full Text] [Related]
30. MYD88 and beyond: novel opportunities for diagnosis, prognosis and treatment in Waldenström's Macroglobulinemia.
Landgren O; Tageja N
Leukemia; 2014 Sep; 28(9):1799-803. PubMed ID: 24573383
[TBL] [Abstract][Full Text] [Related]
31. MYD88 L265P mutation in Waldenstrom macroglobulinemia.
Poulain S; Roumier C; Decambron A; Renneville A; Herbaux C; Bertrand E; Tricot S; Daudignon A; Galiègue-Zouitina S; Soenen V; Theisen O; Grardel N; Nibourel O; Roche-Lestienne C; Quesnel B; Duthilleul P; Preudhomme C; Leleu X
Blood; 2013 May; 121(22):4504-11. PubMed ID: 23532735
[TBL] [Abstract][Full Text] [Related]
32.
Alcoceba M; García-Álvarez M; Medina A; Maldonado R; González-Calle V; Chillón MC; Sarasquete ME; González M; García-Sanz R; Jiménez C
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628381
[TBL] [Abstract][Full Text] [Related]
33. Significances of MYD88
Meng Q; Cao XX; Li J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):578-582. PubMed ID: 28877839
[TBL] [Abstract][Full Text] [Related]
34. Impact of MYD88
Zanwar S; Abeykoon JP; Durot E; King R; Perez Burbano GE; Kumar S; Gertz MA; Quinquenel A; Delmer A; Gonsalves W; Cornillet-Lefebvre P; He R; Warsame R; Buadi FK; Novak AJ; Greipp PT; Inwards D; Habermann TM; Micallef I; Go R; Muchtar E; Kourelis T; Dispenzieri A; Lacy MQ; Dingli D; Nowakowski G; Thompson CA; Johnston P; Thanarajasingam G; Bennani NN; Witzig TE; Villasboas J; Leung N; Lin Y; Kyle RA; Rajkumar SV; Ansell SM; Le-Rademacher JG; Kapoor P
Am J Hematol; 2020 Mar; 95(3):274-281. PubMed ID: 31814157
[TBL] [Abstract][Full Text] [Related]
35. MYD88 (L265P) somatic mutation in marginal zone B-cell lymphoma.
Martinez-Lopez A; Curiel-Olmo S; Mollejo M; Cereceda L; Martinez N; Montes-Moreno S; Almaraz C; Revert JB; Piris MA
Am J Surg Pathol; 2015 May; 39(5):644-51. PubMed ID: 25723115
[TBL] [Abstract][Full Text] [Related]
36. Immunoglobulin heavy chain sequence analysis in Waldenstrom's macroglobulinemia and immunoglobulin M monoclonal gammopathy of undetermined significance.
Rollett RA; Wilkinson EJ; Gonzalez D; Fenton JA; Short MA; Evans PA; Rawstron AC; Owen RG
Clin Lymphoma Myeloma; 2006 Jul; 7(1):70-2. PubMed ID: 16879773
[TBL] [Abstract][Full Text] [Related]
37. Successful treatment of refractory cold hemagglutinemia in MYD88 L265P mutation-negative Waldenström's macroglobulinemia with bortezomib.
Izumi M; Tsunemine H; Suzuki Y; Tomita A; Kusumoto T; Kodaka T; Itoh K; Takahashi T
Int J Hematol; 2015 Aug; 102(2):238-43. PubMed ID: 25794560
[TBL] [Abstract][Full Text] [Related]
38. Detection of MYD88 and CXCR4 mutations in cell-free DNA of patients with IgM monoclonal gammopathies.
Bagratuni T; Ntanasis-Stathopoulos I; Gavriatopoulou M; Mavrianou-Koutsoukou N; Liacos C; Patseas D; Kanellias N; Migkou M; Ziogas DC; Eleutherakis-Papaiakovou E; Roussou M; Fotiou D; Terpos E; Kastritis E; Dimopoulos MA
Leukemia; 2018 Dec; 32(12):2617-2625. PubMed ID: 30026568
[TBL] [Abstract][Full Text] [Related]
39. Origin of Waldenstrom's macroglobulinaemia.
García-Sanz R; Jiménez C; Puig N; Paiva B; Gutiérrez NC; Rodríguez-Otero P; Almeida J; San Miguel J; Orfão A; González M; Pérez-Andrés M
Best Pract Res Clin Haematol; 2016 Jun; 29(2):136-147. PubMed ID: 27825459
[TBL] [Abstract][Full Text] [Related]
40. Molecular characterization of heavy chain immunoglobulin gene rearrangements in Waldenström's macroglobulinemia and IgM monoclonal gammopathy of undetermined significance.
Martín-Jiménez P; García-Sanz R; Balanzategui A; Alcoceba M; Ocio E; Sanchez ML; González M; San Miguel J
Haematologica; 2007 May; 92(5):635-42. PubMed ID: 17488687
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
